Abstract
The activity of two new quinolones, A-56619 and A-56620, was compared in vitro to that of norfloxacin and ciprofloxacin against 6,699 bacterial isolates in four separate clinical laboratories. The overall percentage of strains susceptible to designated concentrations were as follows: 99.1% for norfloxacin (MIC⩽4.0 μ g/ml), 96.1% for ciprofloxacin (MIC⩽1.0 μ g/ml), 96.8% for A-56620 (MIC ⩽ 2.0 μ g/ml) and 96.1% for A-56619 (MIC⩽ 4.0 μ g/ml). For disk diffusion susceptibility tests 10 μ g A-56619 disks are tentatively recommended with interpretive standards of ⩾ 18mm for susceptibility and ⩽ 13mm for resistance; 5 μ g A-56620 disks may be used with tentative standards of ⩾ 19mm for susceptibility and ⩽ 14mm for resistance.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Eliopoulos, G. M., Moellering, A. E., Reiszner, E., Moellering, R. C.: In vitro activities of the quinolone antimicrobial agents A-56610 and A-55620. Antimicrobial Agents and Chemotherapy 1985, 28: 514–520.
National Committee for Clinical Laboratory Standards: Standard methods for dilution antimicrobial susceptibility tests for bacteria which grow aerobically. Approved standard M7-A. Villanova, PA, 1985.
National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A3. Villanova, PA, 1984.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Barry, A.L., Jones, R.N., Thornsberry, C. et al. In vitro activity of the aryl-fluoroquinolones A-56619 and A-56620 and evaluation of disk susceptibility tests. Eur. J, Clin. Microbiol. 5, 18–22 (1986). https://doi.org/10.1007/BF02013455
Issue Date:
DOI: https://doi.org/10.1007/BF02013455